Increasingly immunotherapy trials continue to examine the benefits of PD1/PD-L1 and CTLA4 blockade and will likely be incorporated into the treatment pathways of advanced gastric cancer [158–160]. The gene discussed is CTLA4; the disease is gastric cancer.